Pentracor GmbH

Reduction of Infarct Size after Acute Myocardial Infarct and Stroke, by controlling the immune response through CRP apheresis

  • Stage $500K in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Berlin, Germany
  • Currency EUR
  • Founded January 2010
  • Employees 24
  • Incorporation Type Other
  • Website pentracor.de

Company Summary

Pentracor GmbH produces and markets CRP-adsorbers for extracorporeal therapeutic lowering of C-reactive protein.

In myocardial infarction and stroke, the C-reactive protein (CRP) leads to an increase of the primary damage.

PentraSorb® CRP is CE marked and reimbursed in Germany. A 40 pt clinical trial demonstrated a significant 30% reduction in infarct size after Acute Myocardial Infarction, increased left ventricular output and lower MACE.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free